No CrossRef data available.
Article contents
Paliperidone for a patient with delayed-onset performance and memory dysfunction and neuropsychiatric symptoms associated with carbon monoxide intoxication
Published online by Cambridge University Press: 24 June 2014
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Comment & Critique
- Information
- Copyright
- Copyright © Cambridge University Press 2011
References
1.Ernst, A, Zibrak, JD.Carbon monoxide poisoning. N Engl J Med 1998;339:1603–1608.CrossRefGoogle ScholarPubMed
2.Weaver, LK.Clinical practice: carbon monoxide poisoning. N Engl J Med 2009;360:1217–1225.CrossRefGoogle ScholarPubMed
3.Choi, IS.Carbon monoxide poisoning: systemic manifestations and complications. J Korean Med Sci 2001;16:253–261.CrossRefGoogle ScholarPubMed
4.Hu, MC, Shiah, IS, Yeh, CB, Chen, HK, Chen, CK.Ziprasidone in the treatment of delayed carbon monoxide. Encephalopathy 2006;30:755–757.Google ScholarPubMed
5.Pae, CU, Kim, TS, Lee, C, Paik, IH.Effect of aripiprazole for a patient with psychotic symptoms and parkinsonism associated with delayed-sequelae of carbon monoxide intoxication. J Neuropsychiat Clin Neurosci 2006;18:130–131.CrossRefGoogle ScholarPubMed
6.Leysen, JE, Janssen, PM, Megens, AA, Schotte, A.Risperidone: a novel antipsychotic with balanced serotonin–dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiat 1994;55(Suppl): 5–12.Google Scholar
7.Richelson, E, Souder, T.Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29–39.CrossRefGoogle ScholarPubMed
8.Nasrallah, HA.Atypical antipsychotic-induced metabolic side effects: insights from receptor binding profiles. Mol Psychiat 2008;13:27–35.Google Scholar
9.Fowler, JA, Bettinger, TL, Argo, TR.Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther 2008;30:231–248.Google Scholar
10.Yulug, B, Yildiz, A, Guzel, O, Kilic, E, Schabitz, WR, Kilic, E.Risperidone attenuates brain damage after focal cerebral ischemia in vivo. Brain Res Bull 2006;69:656–659.Google Scholar
11.Correll, CU, Leucht, S, Kane, JM.Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of l-year studies. Am J Psychiat 2004;161:414–425.Google Scholar
12.Tandon, R, Jibson, MD.Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiat 2002;14:123–129.CrossRefGoogle ScholarPubMed
13.Woodward, ND, Purdon, SE, Meltzer, HY, Zald, DH.A metaanalysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007;89:211–224.Google Scholar
14.Keefe, RS, Bilder, RM, Davis, SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiat 2007;64:633–647.CrossRefGoogle ScholarPubMed
15.Grootens, KP, Van Veelen, NM, Peuskens, J et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull 2011;37:352–361.CrossRefGoogle ScholarPubMed
16.Van Veelen, NM, Grootens, KP, Peuskens, J et al. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophr Res 2010;120:191–198.Google Scholar
17.Nussbaum, A, Stroup, TS.Paliperidone for schizophrenia. Cochrane Database Syst Rev 2008;16:CD006369.Google Scholar